Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
T-cell engagers are bispecific antibodies that bind CD3 on T cells and a surface antigen on target cells. Simultaneous binding forms an immune synapse that triggers T-cell activation and lysis of the target cell without the need for antigen presentation. Teclistamab and elranatamab pair CD3 with B-cell maturation antigen (BCMA), while talquetamab binds GPRC5D on myeloma cells. Glofitamab, mosunetuzumab and epcoritamab redirect T cells to CD20, and catumaxomab binds epithelial cell adhesion molecule (EpCAM). Further formats target CD19, CD33, CD123, prostate-specific membrane antigen (PSMA) and mucins, together with anti-CD3 antibodies.
Muromonab is a monoclonal antibody that specifically targets the CD3 receptor on T cells. This antibody effectively blocks cytotoxic T cell activity, serving as a potent immunosuppressive agent. It is primarily used to prevent acute rejection in solid organ transplantation by inhibiting the immune response that can lead to organ rejection.
